Shots:

• The submission is based on 10 PIONEER studies assessing semaglutide vs sitagliptin- empagliflozin- liraglutide and dulaglutide in 9-543 adult patients with type 2 diabetes
• The collective studies result demonstrated reduction in HbA_1c and weight loss with safe & well tolerated data
• Semaglutide (qd) is an oral GLP-1 receptor agonist administered once-daily with its expected approval in the US- the EU and Canada

Ref: Novo Nordisk | Image: The Local Denmark